Stock Forecast

  MyMD Pharmaceuticals, Inc. ( MYMD) Stock. Should you Buy or Sell?    $ 3.59

-0.09 (-2.57 %)



MyMD Pharmaceuticals, Inc. Analysis

Updated on 10-09-2022
Symbol MYMD
Price $3.59
Beta 0.287
Volume Avg. $287.39 thousand
Market Cap $136.63 M
52 Week Range $1.88 - $9.95


MyMD Pharmaceuticals, Inc. opened the day at $3.59 which is -2.57 % on yesterday's close. MyMD Pharmaceuticals, Inc. has a 52 week high of $9.95 and 52 week low of $1.88, which is a difference of $8.07. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $136.63 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy MyMD Pharmaceuticals, Inc. for $136.63 M, it would take 15 years to get your money back. MyMD Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




MyMD Pharmaceuticals, Inc. Stock Forecast - Is MyMD Pharmaceuticals, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreSell
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value


PE Ratio -0.005
Dividend Yiel 0.000
Net Profit Margin 0.000


Valuing MyMD Pharmaceuticals, Inc.


Price Book Value Ratio 8.536 Price To Book Ratio 8.536
Price To Sales Ratio 0.000 Price Earnings Ratio -0.005


How liquid is MyMD Pharmaceuticals, Inc.


Current Ratio 2.409
Quick Ratio 1.936


Debt


Debt Ratio 0.159 Debt Equity Ratio 0.189
Long Term Debt To Capitalization 0.007 Total Debt To Capitalization 0.011



Latest news about MyMD Pharmaceuticals, Inc.


What to Know About Buying Penny Stocks on July 11th

Here's what you need to know about trading penny stocks on July 11th The post What to Know About Buying Penny Stocks on July 11th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Date : 11/07/2022

MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. Benchmark Company Discovery Conference Date: December 2, 2021 Format: 1-on-1 meetings (virtual) Registration: Click here Benzinga Global Small Cap Conference Dates: December 8-9, 2021 Format: Present

Date : 01/12/2021

Week 44 MDA Breakout Stocks - November 2021: Short-Term Picks To Give You An Edge

Two new Breakout Stocks for Week 44 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is up +68.8% YTD despite a record high 24 weeks out 43 weeks this year in negative conditions above the 40 MG level.

Date : 30/10/2021

MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m. ET in Track 1. The conference is being held at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida. MyMD Chief Scientific Officer Adam Kaplin, M.D., Ph.D.

Date : 19/10/2021

MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBD's superior potency over CBD by factor of 8,000 times. Supera-CBD is MyMD's pre-clinical patented synthetic cannabidiol (CBD) derivative that is being developed as a pharmaceutical drug to address anxiety, pain, and neurodegeneration. The study was conducted by Eurofins D

Date : 22/09/2021





About MyMD Pharmaceuticals, Inc.


CEO : Mr. Howard Yeaton
Sector : Healthcare
Industry : Biotechnology

Website : https://www.mymd.com

Exchange : NASDAQ Capital Market

Description :

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.


My Newsletter

Sign Up For Updates & Newsletters